Управление гипергликемией при остром коронарном синдроме. Проблемы и решения

Роль гипергликемии как независимого предиктора неблагоприятного течения и прогноза острого коронарного синдрома (ОКС) у лиц с сахарным диабетом (СД) и без него [1] сложно переоценить. Данная взаимосвязь широко освещена в литературе [2-13], и дискуссии на этот предмет не теряют актуальности. Заболеваемость и смертность от ИБС у пациентов с СД превышает ожидаемые уровни при простом суммировании рисков, указывая на непосредственное влияние гипергликемии на атеро-склеротический процесс [14-16]. При этом стоит отметить, что у пациентов без СД гипергликемия ассоциирована с худшими клиническими исходами и более высокой смертностью от всех причин по сравнению с пациентами, страдающими сахарным диабетом [17-21]. Повышение сахара крови на момент поступления, как правило, воспринимается как реакция на стресс при остром состоянии, однако в ряде случаев может служить маркером уже существующего, но еще не диагностированного сахарного диабета 2-го типа или нарушения толерантности к глюкозе (НТГ) [22]. По данным обсервационных исследований, гипергликемия встречается у 32-38% пациентов в стационаре [23, 24], у 41% тяжелых пациентов с острым коронарным синдромом [25], у 44% пациентов с сердечной недостаточностью [25] и у 80% пациентов после хирургического вмешательства на коронарных артериях [26, 27].

контроль гликемии, острый коронарный синдром, сахарный диабет 2-го типа, глюкометр, glycemic control, acute coronary syndrome, type 2 diabetes, blood glucose meter

1. Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, 2000, 355: 773-778.

2. Yudkin JS, Oswald GA. Stress hyperglycemia and cause of death in non-diabetic patients with myocardial infarction. Br Med J, 1987, 294: 773.

3. Sewdarsen M, Vythilingum S, Jialal I et al. Prognostic importance of admission plasma glucose in diabetic and non-diabetic patients with acute myocardial infarction. Q J Med, 1989, 71: 461-466.

4. Bellodi G, Manicardi V, Malavasi V et al. Hyperglycemia and prognosis of acute myo-cardial infarction in patients without diabetes mellitus. Am J Cardiol, 1989, 64: 885-888.

5. O'Sullivan JJ, Conroy RM, Robinson K et al. In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care, 1991, 14: 758-760.

6. Mak KH, Mah PK, Tey BH et al. Fasting blood sugar level: a determinant for in-hospital outcome in patients with first myocardial infarction and without glucose intolerance. Ann Acad Med Singapore, 1993, 22: 291-295.

7. Leor J, Goldbourt U, Reicher-Reiss H et al. Cardiogenic shock complicating acute myo-cardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med, 1993, 94: 265-273.

8. Wahab NN, Cowden EA, Pearce NJ et al. ICONS Investigators. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol, 2002, 40: 1748-1754.

9. Stranders I, Diamant M, van Gelder RE et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes melli-tus. Arch Intern Med, 2004, 164: 982-988.

10. Wong VW, Ross DL, Park K et al. Hyperglycemia: still an important predictor of adverse outcomes following AMI in the reperfusion era. Diabetes Res Clin Pract, 2004, 64: 85-91.

11. Hadjadj S, Coisne D, Mauco G et al. Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. Diabet Med 2004, 21: 305-310.

12. Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C Kimura et al. Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J, 2005, 150: 814-820.

13. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation, 2005, 111: 3078-3086.

14. Волков В.И., Серик С.А. Ишемическая болезнь сердца при сахарном диабете 2 типа: эпидемиология, патофизиология и профилактика. Международный медицинский журнал, 2006, 4: 41-47

15. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol., 2002, 1: 1-9.

16. Morgan KP, Kapur A, Baett KJ. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potentiol target for intervention. Heart, 2004, 90: 732-738.

17. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose, Independent risk factor for long-term prognosis after myocardial infarction even in nondia-betic patients. Diabetes Care, 1999, 22: 1827-1831.

18. Timmer JR, van der Horst IC, Ottervanger JP Henriques JP, Hoorntje JC, de Boer MJ et al. Myocardial Infarction Study Group. Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. Am Heart J, 2004, 148: 399-40.

19. Kadri Z, Danchin N, Vaur L, Cottin Y, Gueret P Zeller M et al. Major impact of admission gly-caemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart, 2006. 2000, 92: 910-915.

20. Bauters C, Ennezat PV, Tricot O, Lauwerier B, Lallemant R, Saadouni H et al. Stress hypergly-caemia is an independent predictor of left ventricular remodelling after first anterior myocar-dial infarction in non-diabetic patients. Eur HeartJ, 2007, 28: 546-552.

21. Volkov V.I., Serik S.A. Coronary artery disease with type 2 diabetes: epidemiology, pathophysiology and prevention. Mezhdunarodniy Meditsinskiy Zhurnal, 2006, 4: 41-47.

22. Naber CK, Mehta RH, Junger C, Zeymer U, Wienbergen H, Sabin GV et al. Impact of admission blood glucose on outcomes of nondiabetic patients with acute ST-elevation myocardial infarction (from the German Acute Coronary Syndromes [ACOS] Registry). Am J Cardiol., 2009, 103: 583-587.

23. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet, 2002, 359: 2140-2144.

24. Umpierrez GE, Isaacs SD, Bazargan N et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87(3): 978-982.

25. Cook CB, Kongable GL, Potter DJ, et al. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. Journal of Hospital Medicine, 2009, 4(9): E7-E14.

26. Kosiborod M, Inzucchi SE, Spertus JA et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation, 2009, 119(14): 1899- 1907.

27. Schmeltz LR, DeSantis AJ, Thiyagarajan V et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care, 2007, 30(4): 823-828.

28. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. New England Journal of Medicine, 2001, 345(19): 1359-1367.

29. Gokhroo R, Mittal SR. Electrocardiographic correlates of hyperglycemia in acute myocardial infarction. Int J Cardiol, 1989, 22: 267-269.

30. Marfella R, Nappo F, De Angelis L et al. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia, 2000, 43: 571-575.

31. D'Amico M, Marfella R, Nappo F et al. High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia, 2001, 44: 464-470.

32. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol, 2000, 11: 9-23.

33. Valgimigli M, Merli E, Malagutti P et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys, 2003, 420: 255-261.

34. Giugliano D, Marfella R, Coppola L et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation, 1997, 95: 1783-1790.

35. Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation, 1998, 97: 1695-1701.

36. Iwakura K, Ito H, Ikushima M, Kawano S et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol, 2003, 41: 1-7.

37. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000; 101: 948-954.

38. Xi G, Shen X, Maile LA, Wai C, Gollahon K, Clemmons DR. Hyperglycemia enhances IGF-I-stimulated Src activation via increasing Nox4-derived reactive oxygen species in a PKCzeta-dependent manner in vascular smooth muscle cells. Diabetes, 2012, 61: 104-113.

39. Ning J, Xi G, Clemmons DR. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology, 2011, 152: 3143-3154.

40. Kersten JR, Schmeling TJ, Orth KG et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol, 1998, 275: 721-725.

41. Poulsen SH, Jensen SE, Tei C et al. Value of the Doppler index of myocardial performance in the early phase of acute myocardial infarction. J Am Soc Echocardiogr, 2000, 13: 723-730.

42. Sakamoto T, Ogawa H, Kawano H et al. Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost, 2000, 83: 475-479.

43. Gresele P, Guglielmini G, De Angelis M et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type 2 diabetes mellitus. Journal of the American College of Cardiology, 2003, 41(6): 1013-1020.

44. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest, 1979, 63: 485-493.

45. Ceriello A, Giugliano D, Quatraro A et al. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism, 1989, 38: 1162-1163.

46. Ceriello A, Giacomello R, Stel G et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of the oxidative stress. Diabetes, 1995, 44: 924-928.

47. Ceriello A, Giugliano D, Quatraro A et al. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia, 1988, 31: 889-891.

48. Pandolfi A, Giaccari A, Cilli C et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetologica, 2001, 38(2): 71-76.

49. Marfella R, Siniscalchi M, Esposito K et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care, 2003, 26: 3129-3135.

50. Marfella R, Esposito K, Giunta R et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation, 2000, 101: 2247-2251.

51. Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation, 2002, 106: 2067- 2072.

52. Ceriello A, Quagliaro L, Piconi L et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes, 2004, 53: 701-710.

53. Ceriello A. Acute hyperglycaemia: a ‘new’ risk factor during myocardial infarction. Eur Heart J, 2005, 26(4): 328-331.

54. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol, 2003, 91(Suppl.): 12A-16A.

55. Ceriello A. Acute hyperglycaemia and oxidative stress generation. Diabet Med, 1997, 14: 45-49.

56. Ceriello A, Bortolotti N, Crescentini A et al. Antioxidant defenses are reduced during oral glucose tolerance test in normal and non-insulin dependent diabetic subjects. Eur J Clin Invest, 1998, 28: 329-333.

57. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, 1996, 271: 1424-1437.

58. Shishehbor MH, Aviles RJ, Brennan ML et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 2003, 289: 1675-1680.

59. Pennathur S, Wagner JD, Leeuwenburgh C et al. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest, 2001, 107: 853-860.

60. Ceriello A, Quagliaro L, D'Amico M et al. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes, 2002, 51: 1076-1082.

61. Marfella R, Quagliaro L, Nappo F et al. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest, 2001, 108: 635-636.

62. Ceriello A, Taboga C, Tonutti L et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment. Circulation, 2002, 106: 1211-1218.

63. Моругова Т.В., Шестакова М.В. Индивидуальные и госпитальные глюкометры: баланс между несомненной пользой и безопасностью. Consilium Medicum, 2014, 4: 19-22.

64. Donatelli F et al. Epidural Anesthesia and Analgesia Decrease the Postoperative Incidence of Insulin Resistance in Preoperative Insulin-Resistant Subjects Only. Anesth. Analg., 2007, 104: 1587-1593.

65. Руднов В.А. Клиническая значимость и возможные пути коррекции гипергликемии при критических состояниях. Consilium Medicum, 2006, 08, 7: 23.

66. Hellinger WC, Grant RL, Hernke DA. Glucose meters and opportunities for in-hospital transmission of infection: quantitative assessment and management with and without patient assignment. Am J Infect Control, 2011, 39: 752-756.

67. Nichols JH. Blood glucose testing in the hospital: error sources and risk management. J Diabetes Sci Technol, 2011, 5(1): 173-177.

68. Wilkerson K, Hodge EM. P9-081: Glucometer cleaning: a process improvement following a stste survey. Am J Infect Conrol, 2011, 39(5): 165.

69. Kost GJ, Tran NK, Louie RF et al. Assessing the performance of handheld glucose testing for critical care. Diabetes Technol Therapeut, 2008, 10(6): 445-1.

70. Аметов А.С., Черникова Н.А., Пьяных О.П., Ермакова Е.А. Роль и место глюкокардиомониторирования в оценке кардиологических рисков у пациентов с сахарным диабетом 2 типа. Сахарный диабет 2 типа: проблемы и решения. Под ред. А.С. Аметова. Москва, «ГЭОТАР-Медиа», 2013: 821-851.

71. Аникин В.В., Савин В.В. Особенности проявления аритмий при стенокардии, сочетающейся с сахарным диабетом II типа. Кардиология, 1999, 12: 24-28.

72. Иванова Л.А. Эффект влияния лечения различными сахароснижающими препаратами на летальность и смертность у больных с острым коронарным синдромом и сахарным диабетом 2 типа. Третий Российский Диабетологический Конгресс. Тез. докл. М. 2004: 175-176.

73. Легкогонов А.В. Результаты и перспективы изучения поздних потенциалов желудочков. Кардиология, 1997, 10: 57-66.

74. Савельева И.В., Бакалов С.А., Голицын СП. Стратификация больных с желудочковыми аритмиями по группам риска внезапной смерти. Кардиология, 1997, 8: 82- 95.

75. Сулимов В.А., Калашников В.Ю. Современные методы диагностики аритмий. Сердце, 2002, 2: 65-71.

76. Чирейкин Л.В., Быстров Я.Б., Шубик Ю.В. Поздние потенциалы желудочков в современной диагностике и прогнозе течения заболеваний сердца. Вестник аритмологии, 1999, 13: 61-74.

77. Cefalu WT. Glycemic Targets and Cardiovascular Disease. N Engl J Med., 2008, June 12, 358: 2633-2635. Goede P, Lund-Andersen H, Parving HH et al. Effect of multifactorial intervention on mortality in tipe 2 diabetes. N Engl J Med, 2008, 358: 580-589.

78. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl J Med, 1993, 329: 977-986.

79. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352: 837-853.

80. Van den Berghe G: How does blood glucose control with insulin save lives in intensive care? J Clin Invest, 2004, 114: 1187-1195.

81. Umpierrez GE&A.E.K. ICU care for patients with diabetes. Current Opinion in Endocrinology and Diabetes, 2004, 11: 75-81.

82. McCowen KC, Malhotra A &Bistrian BR. Stress-induced hyperglycemia. Crit Care Clinics, 2001, 17(1):107-124.

83. Farrokhi F, Smiley D, Umpierrez GE. Glycemic control in non-diabetic critically patients. Best Practice & Research Clinical Endocrinology &Metabolism, 2011, 25: 813-824.

84. Smooke S., Fonarow G.C. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J, 2005, 149: 168-174.

85. Malmberg К, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A. et al on. behalf of the DIGAMI I study group. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effect on mortality at 1year. J Am Coll Сardial, 1995, 26: 57-65. The CREATE-ECLA trial group. Effect of glucose-insulin -- potassium infusion on mortality in patients acute ST- segment elevation myocardial infarction: The CREATE -- ECLA randomized controlled trial. JAMA, 2005, 293: 437-446.

86. Malmberg К, Ryden L, Wedel H, Birkeland K, Dicksrein K, Efendic S et al. Investigator Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2 study): Effects on mortality and morbidity. Eur Heart J, 2005, 26: 650-661.

87. Sarah E, Siegelaar LK, Scott J, Jacober J, Devries H. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction. Diabetes Care, 2011, 34: 855-857.

88. Morugova T.V., Shestakova M.V. Individual and hospital-based blood glucose meters: balance between the undoubted benefit and safety. Consilium Medicum, 2014, 4: 19-22.

89. Rudnov V.A. Clinical relevance and possible ways of managing hyperglycemia in critical conditions. Consilium Medicum, 2006, 08, 7: 23.

90. Ametov A.S., Chernikova N.A., Pyanykh O.P., Ermakova E.A. The role and place of glucose and cardio-monitoring in assessing cardiac risks in patients with type 2 diabetes. Diabetes mellitus type 2: issues and solutions. Ed. by А.S. Ametov. Moscow, GEOTAR-Media, 2013: 821-851.

91. Anikin V.V., Savin V.V. Specific manifestations of arrhythmia in angina combined with type II diabetes mellitus. Kardiologiya, 1999, 12: 24-28.

92. Ivanova L.A. The effect of treatment with different antidiabetic drugs on mortality and mortality in patients with acute coronary syndrome and type 2 diabetes. Third Russian Diabetes Congress. Abstr. of reports M. 2004: 175-176.

93. Legkogonov A.V. Results and prospects of the study of ventricular late potentials. Kardiologiya, 1997, 10: 57-66.

94. Savelyeva I.V., Bakalov S.A., Golitsyn S.P. Stratification of patients with ventricular arrhythmias by risk of sudden death. Kardiologiya, 1997, 8: 82-95.

95. Sulimov V.A., Kalashnikov V.Y. Current methods for diagnosis of arrhythmia. Serdtse, 2002, 2: 65-71.

96. Chireykin L.V., Bystrov Y.B., Shubik Y.V. Ventricular late potentials in current diagnosis and prognosis of heart disease. Vestnik Aritmologii, 1999, 13: 61-74.